EUVIMEDEUVIMED entdecken
Crossref

Duration of and time to response in oncology clinical trials from the perspective of the estimand framework

Hans-Jochen Weber iD, Stephen Corson iD, Jiang Li, François Mercier, Satrajit Roychoudhury iD, Martin Oliver Sailer, Steven Sun iD, Alexander Todd, Godwin Yung, Industry Working Group on Estimands in Oncology

Pharmaceutical Statistics · 2024-01 · 23 (1) · 91-106

DOI: 10.1002/pst.2340 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutical Statistics, online erschienen am 02.10.2023. Verfasst von Hans-Jochen Weber und 9 weiteren Autor:innen. Beteiligte Einrichtung: Novartis AG, Basel, Switzerland. Hauptthemen laut MEDLINE: Neoplasms, Research Design. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Duration of response (DOR) and time to response (TTR) are typically evaluated as secondary endpoints in early‐stage clinical studies in oncology when efficacy is assessed by the best overall response and presented as the overall response rate. Despite common use of DOR and TTR in particular in single‐arm studies, the definition of these endpoints and the questions they are intended to answer remain unclear. Motivated by the estimand framework, we present relevant scientific questions of interest for DOR and TTR and propose corresponding estimand definitions. We elaborate on how to deal with relevant intercurrent events which should follow the same considerations as implemented for the primary response estimand. A case study in mantle cell lymphoma illustrates the implementation of relevant estimands of DOR and TTR. We close the paper with practical recommendations to implement DOR and TTR in clinical study protocols.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsResearch DesignAdultHumansData Interpretation, StatisticalMedical OncologyClinical Trials as Topic

Stichwörter der Autor:innen

clinical trialduration of responseestimandtime to response

Autor:innen und Institutionen

  • Novartis AG, Basel, Switzerland.
  • Phastar, Glasgow, UK.
  • BeiGene, Ridgefield Park, New Jersey, USA.
  • Hoffmann-La Roche Ltd, Basel, Switzerland.
  • Pfizer, New York, New York, USA.
  • Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.

ORCID-Profile: Hans-Jochen Weber, Stephen Corson, Satrajit Roychoudhury, Steven Sun

Zitieren

APA

Weber, H. J., Corson, S., Li, J., Mercier, F., Roychoudhury, S., Sailer, M. O., Sun, S., Todd, A., Yung, G., & Industry Working Group on Estimands in Oncology (2024). Duration of and time to response in oncology clinical trials from the perspective of the estimand framework. Pharmaceutical Statistics, 23(1), 91-106. https://doi.org/10.1002/pst.2340

Vancouver

Weber HJ, Corson S, Li J, Mercier F, Roychoudhury S, Sailer MO, et al. Duration of and time to response in oncology clinical trials from the perspective of the estimand framework. Pharmaceutical Statistics. 2024;23(1):91-106. doi:10.1002/pst.2340

BibTeX
@article{Weber2024,
  author = {Weber, Hans-Jochen and Corson, Stephen and Li, Jiang and Mercier, François and Roychoudhury, Satrajit and Sailer, Martin Oliver and Sun, Steven and Todd, Alexander and Yung, Godwin and Industry Working Group on Estimands in Oncology, Industry Working Group on Estimands in Oncology},
  title = {Duration of and time to response in oncology clinical trials from the perspective of the estimand framework},
  journal = {Pharmaceutical Statistics},
  year = {2024},
  volume = {23},
  number = {1},
  pages = {91--106},
  doi = {10.1002/pst.2340}
}
Kostenlos starten →